Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Fernández Arráiz, Gerardo"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    Síndrome inflamatorio multisistémico asociado a COVID-19 en pacientes pediátricos
    (Universidad Técnica de Ambato/Facultad de Ciencias de la Salud/Carrera de Medicina, 2022-09-01) Fernández Arráiz, Gerardo; Acosta, Josué, Dr. Esp.
    Pediatric Multisystem Inflammatory Syndrome (P-MIS) linked to SARS-CoV-2 is a generalized inflammatory reaction that develops approximately 4-6 weeks after COVID-19 illness. The aim of the article was to analyze the immunopathogenesis, diagnosis and treatment of P-MIS. A systematic literature review was performed using databases such as Embase, Redalyc, LILACS, SciELO, Springer, Elsevier, EBSCO and Google Scholar and the keywords: Coronavirus disease, Kawasaki disease, child, intravenous immunoglobulins. Inclusion criteria were: full articles, published between the years 2019- 2022, in English and Spanish. Of the 273 articles found, 243 articles were rejected for not meeting the established criteria, with 30 articles selected as eligible. According to the results, SIM-P is characterized by fever, myocardial injury, shock and development of coronary artery aneurysms; laboratory tests show: elevation of markers of inflammation, changes in coagulation tests, especially significant elevation of D-dimer and fibrinogen and elevation of markers of myocardial injury, troponin and natriuretic peptide. Phase 1 treatment occurs with the administration of intravenous immunoglobulin G (IVIG), corticosteroids, low molecular weight heparin in a prophylactic dose; in phase 2, treatment consists of administration of a second dose of IVIG, progressive reduction of prednisone and use of biological therapy; and, in phase 3, infliximab or tocilizumab is used. In conclusion, SIM-P has elevated inflammatory markers and multi-organ involvement, with no associated bacterial diagnosis, with evidence of infection or recent exposure to SARS- CoV-2.

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify